Publications by authors named "Ravi Velaga"

Claim this Profile
F
Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers.
Jing Li, Ravi Velaga, Yuko Takano, Norikazu Masuda

Int J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
Yumiko Akita, Ravi Velaga, Madoka Iwase, Satoko Shimada, Toyone Kikumori

Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.
Yumiko Akita, Ravi Velaga, Madoka Iwase, Satoko Shimada, Toyone Kikumori

Breast Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Tomomi Nishimura, Ravi Velaga, Norikazu Masuda, Kosuke Kawaguchi, Shuji Kawaguchi

Cancer Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.
Ravi Velaga, Kevin M Koo, Paul N Mainwaring

Immunotherapy· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncobiology and treatment of breast cancer in young women.
Rakesh Kumar, Catarina Abreu, Masakazu Toi, Sunil Saini, Sandra Casimiro, Ravi Velaga

Cancer Metastasis Rev· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours.
Ravi Velaga, Sunao Tanaka, Masakazu Toi

Cancer Drug Resist· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Ravi Velaga

BMC Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-Generation Clinical Trials and Research with Successful Collaborations.
Masakazu Toi, Ravi Velaga

Adv Exp Med Biol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma.
Seiichiro Katagiri, Hideki Makishima, Kenko Azuma, Yasuhito Nannya, Yuu Saitoh, Ravi Velaga

Haematologica· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis